Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$147.24

-1.61 (-1.08%)

12:46
01/11/17
01/11
12:46
01/11/17
12:46

TESARO call volume above normal and directionally bullish

Bullish option flow detected in TESARO with 1,264 calls trading, 1.8x expected, and implied vol increasing almost 2 points to 54.80%. Jan-17 155 calls and Jan-18 110 puts are the most active options, with total volume in those strikes near 540 contracts. The Put/Call Ratio is 0.51. Earnings are expected on February 23rd.

  • 11

    Jan

  • 30

    Jun

TSRO Tesaro
$147.24

-1.61 (-1.08%)

12/27/16
FBRC
12/27/16
NO CHANGE
Target $151
FBRC
Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Outperform
ARIAD acquisition supports potential takeout premium for TESARO, says Leerink
Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TODAY'S FREE FLY STORIES

AKZOY

AkzoNobel

$29.20

-0.45 (-1.52%)

06:45
07/25/17
07/25
06:45
07/25/17
06:45
Earnings
AkzoNobel reports Q2 revenue EUR3.71B vs. EUR3.79B last year »

Reports Q2 EBIT EUR491M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$22.95

0.71 (3.19%)

, LLY

Eli Lilly

$84.74

0.08 (0.09%)

06:45
07/25/17
07/25
06:45
07/25/17
06:45
Recommendations
Nektar, Eli Lilly analyst commentary  »

Jefferies views Nektar…

NKTR

Nektar

$22.95

0.71 (3.19%)

LLY

Eli Lilly

$84.74

0.08 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 11

    Sep

AVY

Avery Dennison

$93.96

0.07 (0.07%)

06:45
07/25/17
07/25
06:45
07/25/17
06:45
Earnings
Avery Dennison reports Q2 adjusted EPS $1.31, consensus $1.21 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPLA

Capella Education

$88.05

0.1 (0.11%)

06:44
07/25/17
07/25
06:44
07/25/17
06:44
Hot Stocks
Capella Education sees FY17 revenue up 3.0% »

Sees FY17 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CPLA

Capella Education

$88.05

0.1 (0.11%)

06:43
07/25/17
07/25
06:43
07/25/17
06:43
Hot Stocks
Capella Education sees Q3 revenue 2.0%-3.0% vs. last year »

Sees Q3 consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FBC

Flagstar Bancorp

$30.09

0.15 (0.50%)

06:42
07/25/17
07/25
06:42
07/25/17
06:42
Earnings
Flagstar Bancorp reports Q2 EPS 71c, consensus 61c »

Reports Q2 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 11

    Aug

MFG

Mizuho Financial Group

06:41
07/25/17
07/25
06:41
07/25/17
06:41
Hot Stocks
Mizuho Securities to proceed with application for establishing EU subsidiary »

Mizuho Securities Co., a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPLA

Capella Education

$88.05

0.1 (0.11%)

06:41
07/25/17
07/25
06:41
07/25/17
06:41
Earnings
Capella Education reports Q2 cont ops EPS 90c, consensus 80c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PLYM

Plymouth Industrial REIT

$17.35

0.2475 (1.45%)

06:39
07/25/17
07/25
06:39
07/25/17
06:39
Hot Stocks
Plymouth Industrial REIT to acquire Airport Business Park in Memphis for $7.8M »

Plymouth Industrial REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$311.50

4.3 (1.40%)

06:38
07/25/17
07/25
06:38
07/25/17
06:38
Recommendations
NetEase analyst commentary  »

NetEase price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AXE

Anixter

$78.85

0.5 (0.64%)

06:37
07/25/17
07/25
06:37
07/25/17
06:37
Hot Stocks
Anixter sees FY17 organic sales growth up 3.0%-5.0% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CIT

CIT Group

$48.90

-0.09 (-0.18%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Earnings
CIT Group reports Q2 operating EPS ex-items 68c, consensus 60c »

Reports Q2 revenue $605M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TSLA

Tesla

$342.52

14.12 (4.30%)

, FB

Facebook

$166.00

1.57 (0.95%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Hot Stocks
Musk says Zuckerberg's knowledge of artificial intelligence 'limited' »

In response to a tweet…

TSLA

Tesla

$342.52

14.12 (4.30%)

FB

Facebook

$166.00

1.57 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 02

    Aug

  • 08

    Aug

  • 13

    Sep

  • 02

    Oct

BIIB

Biogen

$284.70

1.78 (0.63%)

06:36
07/25/17
07/25
06:36
07/25/17
06:36
Hot Stocks
Biogen announces updated strategic framework »

Biogen announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

, POAHY

Porsche

$5.82

-0.03 (-0.51%)

06:35
07/25/17
07/25
06:35
07/25/17
06:35
Periodicals
VW CEO criticizes Porsche labor chief's remarks on Audi, Reuters says »

Volkswagen (VLKAY) CEO…

VLKAY

Volkswagen

$32.19

-0.79 (-2.40%)

POAHY

Porsche

$5.82

-0.03 (-0.51%)

AUDVF

Audi AG

$835.60

-4.8 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$78.85

0.5 (0.64%)

06:35
07/25/17
07/25
06:35
07/25/17
06:35
Earnings
Anixter reports Q2 adjusted EPS $1.36, consensus $1.34 »

Reports Q2 revenue $2.0B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

AEL

American Equity

$28.06

0.06 (0.21%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Downgrade
American Equity rating change  »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

TRMB

Trimble

$38.20

0.49 (1.30%)

06:34
07/25/17
07/25
06:34
07/25/17
06:34
Hot Stocks
Trimble adds first partner in Latin America to Vantage network »

Trimble announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 02

    Aug

  • 14

    Aug

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Hot Stocks
Supervalu sees FY18 net earnings from continuing operations $51M-$70M »

Sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BIIB

Biogen

$284.70

1.78 (0.63%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Biogen raises FY17 adjusted EPS view to $20.80-$21.40 from $20.45-$21.25 »

FY17 consensus $20.38.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

GPK

Graphic Packaging

$13.77

0.04 (0.29%)

06:33
07/25/17
07/25
06:33
07/25/17
06:33
Earnings
Graphic Packaging reports Q2 adj. EPS 15c, consensus 15c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Hot Stocks
Breaking Hot Stocks news story on PulteGroup »

PulteGroup believes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SVU

Supervalu

$3.25

-0.01 (-0.31%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
Supervalu reports Q1 adjusted EPS 9c, consensus 11c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MORE

Monogram Residential Trust

$11.95

0.01 (0.08%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Downgrade
Monogram Residential Trust rating change  »

Monogram Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.42

0.11 (0.45%)

06:32
07/25/17
07/25
06:32
07/25/17
06:32
Earnings
PulteGroup reports Q2 adjusted EPS 47c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.